<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694797</url>
  </required_header>
  <id_info>
    <org_study_id>642/09</org_study_id>
    <nct_id>NCT01694797</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metoprolol Succinate Extended-Release Tablets 50 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of TOPROL-XL® (Containing Metoprolol Succinate) Extended-Release Tablets 50 mg of AstraZeneca LP Wilmington, DE in Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor adverse events, safety and tolerance Metoprolol
      Succinate Extended-Release Tablets 50 mg under fasting conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two sequence, single dose,
      crossover, oral bioequivalence study of Metoprolol Succinate Extended-Release tablets 50 mg
      of Dr. Reddy's Laboratories Limited,under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose (0.00) and 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 11.00, 12.00, 13.00, 14.00, 15.00, 16.00, 18.00, 20.00, 24.00, 36.00 and 48.00 hours post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metoprolol Succinate ER Tablets, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOPROL-XL ER Tablets 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOPROL-XL ER Tablets 50 mg of AstraZeneca</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Succinate</intervention_name>
    <arm_group_label>Metoprolol Succinate ER Tablets, 50 mg</arm_group_label>
    <arm_group_label>TOPROL-XL ER Tablets 50 mg</arm_group_label>
    <other_name>TOPROL-XL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects were selected based on the following inclusion criteria:

          -  Provide written informed consent.

          -  Must be healthy, adult, human beings between 18 and 45 years of age(both inclusive)
             weighing at least 50 kg.

          -  Having a body mass index between 18.5 and 24.9 (both inclusive),calculated as weight
             in Kg/height in m2

          -  Must be of normal health as determined by medical history, physical examination and
             laboratory investigation performed within 28 days prior to the commencement of the
             study.(Laboratory values must be within normal limits or considered by the
             physician/investigator to be of no clinical significance).

          -  Female Subjects of child bearing potential practicing an acceptable method of birth
             control for the duration of the study as judged by the investigator (s),such as
             condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

          -  surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)

        Exclusion Criteria:

        The subjects were excluded based on the following criteria during screening and during the
        study:

          -  Incapable of understanding the informed consent.

          -  Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

          -  Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

          -  Oral temperature is below 95.0°F or above 98.6°F.

          -  Pulse rate below 50/min or above 100/min.

          -  History of hypersensitivity or idiosyncratic reaction to investigational drug product
             or any other related drugs.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function.

          -  Consumption of grapefruit for the past ten days prior to the check-in, in each period.

          -  Habit of tobacco chewing.

          -  Habit of alcoholism and difficulty in abstaining from alcohol during the sample
             collection period.

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking during sample collection period.

          -  Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee,
             chocolates and cola drinks) during the sample collection period.

          -  Intake of over the counter (OTC) or prescribed medications and enzyme modifying
             medication or systemic medication for the last 30 days before dosing.

          -  Clinically significant abnormalities and lor with significant diseases.

          -  Confirmed positive in alcohol screening.

          -  Confirmed positive in selected drug of abuse.

          -  Participated in any other clinical investigation using experimental drug/donated blood
             in past 90 days before the date of start of study.

          -  Confirmed positive in urine pregnancy test.

          -  Female detected to be pregnant, breast feeding or who is likely to become pregnant
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. P. Vijaya Lakshmi, Clinical Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Private Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

